Wednesday, March 12, 2025 3/12/2025

Parasite and host cell factors involved in the formation and persistence of Plasmodium vivax hypnozoites

Award Number: R01AI172824
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

This application is in response to the NIAID RFA-AI-21-075 entitled “Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens”, which explicitly states the study of P. vivax hypnozoites as a research objective. P. vivax malaria burdens people within a wide global range and is more pathogenic than previously appreciated. The parasite’s epidemiology and clinical impact is governed by latent liver stages called hypnozoites, which are the source of relapsing blood stage infection. The molecular regulation of hypnozoite stage formation, persistence and activation in hepatocytes has until recently remained unstudied, mainly due to the lack of laboratory tools for this parasite. This has changed of the past ten years with the development of our robust human liver-chimeric mouse model (FRG huHep mouse) that enables the detailed analysis of hypnozoite formation and persistence as well the occurrence of relapses and robust in vitro primary hepatocyte models of infection. In addition, with partners we have recently developed the genetically defined P. vivax Chesson strain for use in hypnozoite studies, replacing complex field-isolate derived sporozoites for infection. With these tools, the goals of this application are the identification of the parasite molecular drivers of hypnozoite formation and persistence and host hepatocyte factors that impact hypnozoite formation and persistence. We will achieve these goals through three independent but complementary aims. In Aim 1 we will generate and interrogate hypnozoite gene expression data with emphasis on factors that are known to regulate quasi-persistence in salivary gland sporozoites. Candidate factors such as AP2 transcription factors, the eIF2a/IK2/UIS2 translational repression system and the, SAP1 and PUF stress granule mRNA storage system will undergo comprehensive examination in P. vivax hypnozoites. Implicated factors that might drive and maintain hypnozoite persistence will then be functionally interrogated using transgene expression and knockout as well as overexpression in a rodent malaria model. In aim 2, we will establish a P. vivax transgenesis system using sporozoite transfection and the Saimiri monkey infection model to establish P. vivax reporter gene-expressing parasite lines, including a line that expresses a hypnozoite-specific marker GRP94, recently identified by us. We will also functionally analyze factors in P. vivax that show strong persistence phenotypes in aim 1 to directly interrogate their role in hypnozoite formation and persistence. In aim 3, we will identify and interrogate host factors with emphasis on host defenses and metabolism in hypnozoite-infected hepatocytes. Host factors that are associated with hypnozoite formation and persistence will be functionally analyzed using siRNA-mediated knockdown and overexpression techniques in an in vitro hypnozoite infection model. Together, this application will gain unprecedented insights into the parasite-intrinsic molecular regulation of liver stage latency as well as the host factors that can further shape the latency phenotype. The findings might lead to the identification of new parasite-targeted and host-targeted therapeutics that prevent relapsing malaria infection.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $742,943 )
2025	2025	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	3	1/16/2025	NON-COMPETING CONTINUATION	$742,943
														Subtotal = $742,943

Issue Date FY: 2024 ( Subtotal = $792,319 )
2024	2024	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	001	2	5/23/2024	NON-COMPETING CONTINUATION	$79,231
2024	2024	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	2	1/12/2024	NON-COMPETING CONTINUATION	$713,088
														Subtotal = $792,319

Issue Date FY: 2023 ( Subtotal = $823,362 )
2023	2023	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	001	1	9/20/2023	NEW	$164,672
2023	2023	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	1	2/9/2023	NEW	$658,690
														Subtotal = $823,362

Grand Total All Awards = $2,358,624

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Parasite and host cell factors involved in the formation and persistence of Plasmodium vivax hypnozoites

Award Number: R01AI172824

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer